MNPR · NASDAQ
Monopar Therapeutics (MNPR) Stock Price & Fundamentals
Monopar Therapeutics (MNPR) closed at $515.21 on Oct 9, 2026, up 1.20% from the previous close of $509.08.
Share price, past year
1Y +3.27%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $515.21 |
| Sep 30, 2026 | $503.68 |
| Aug 31, 2026 | $461.59 |
| Jul 31, 2026 | $451.48 |
| Jun 30, 2026 | $468.51 |
| May 29, 2026 | $497.43 |
| Apr 30, 2026 | $497.17 |
| Mar 31, 2026 | $501.05 |
| Feb 27, 2026 | $526.33 |
| Jan 30, 2026 | $543.87 |
| Dec 31, 2025 | $518.04 |
| Nov 28, 2025 | $505.87 |
| Oct 31, 2025 | $496.33 |
Key statistics
- Market cap
- $3.46B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$17.84M
- Shares outstanding
- 6.7M
- Dividend yield
- —
- 52-week range
- $445.60 – $544.94
Monopar Therapeutics's market cap is $3.46B, based on a share price of $515.21 and 6.7M shares outstanding as of Jun 30, 2026.
Financials
Monopar Therapeutics reported revenue of $0.00 for fiscal 2025.
Monopar Therapeutics reported a net loss of $13.72M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | — | −$13.72M | — | — | — |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$15.59M | — | — | — |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$4.22M | — | −$0.45 | — |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$3.23M | — | −$0.35 | — |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$16.55M | — | −$1.89 | — |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$1.19M | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$3.89M | — |
| Q4 FY2019ended Dec 31, 2019 | $0.00 | — | — |
| Q3 FY2019ended Sep 30, 2019 | $0.00 | — | — |
| Q2 FY2019ended Jun 30, 2019 | $0.00 | — | — |
| Q1 FY2019ended Mar 31, 2019 | $0.00 | — | — |
| Q4 FY2018ended Dec 31, 2018 | $0.00 | — | — |
| Q3 FY2018ended Sep 30, 2018 | $0.00 | — | — |
| Q2 FY2018ended Jun 30, 2018 | $0.00 | — | — |
Company profile
- Name
- Monopar Therapeutics
- Ticker
- MNPR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1000 Skokie Blvd Suite 350, Wilmette, IL 60091
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001645469
Recent SEC filings
- Aug 12, 2026
- Aug 12, 2026
- Jul 22, 2026
- Jun 30, 2026
- Jun 26, 2026
- Jun 23, 2026
- May 29, 2026
- May 19, 2026
Frequently asked questions
What is Monopar Therapeutics's stock price?
Monopar Therapeutics (MNPR) closed at $515.21 on Oct 9, 2026, up 1.20% from the previous close of $509.08.
What is Monopar Therapeutics's market cap?
Monopar Therapeutics's market cap is $3.46B, based on a share price of $515.21 and 6.7M shares outstanding as of Jun 30, 2026.
How much revenue does Monopar Therapeutics make?
Monopar Therapeutics reported revenue of $0.00 for fiscal 2025.
Does Monopar Therapeutics pay a dividend?
Monopar Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Monopar Therapeutics's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures